Indeed, we did observe that DCC-3116 treatment modestly inhibited the growth of one human KRASG12C mutant lung cancer cell line, NCI-H358, both in vitro and in vivo, suggesting that ULK1/2 inhibition as a monotherapy may indeed have significant single-agent activity in certain settings. The gene discussed is ULK1; the disease is lung carcinoma.